
Exscientia Receives First CTA Approval to Initiate IGNITE-AI, a Phase 1/2 Trial of EXS-21546 in Patients with Advanced Solid Tumours
— Study will enrol up to 110 patients in immunotherapy relapsed/refractory RCC and NSCLC — — Exscientia’s A2A biomarker signature for patient selection will be […]













